AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|AAPL323.12+6.27 (+1.98%) ▲|ABBV259.94+3.52 (+1.37%) ▲|ABT109.72-0.65 (-0.58%) ▼|ACN188.13-1.63 (-0.86%) ▼|ADBE288.66-4.13 (-1.41%) ▼|AMAT444.40-13.99 (-3.05%) ▼|AMD457.06-13.66 (-2.90%) ▼|AMGN433.06+3.18 (+0.74%) ▲|AMT175.51-0.19 (-0.11%) ▼|AMZN254.66-5.12 (-1.97%) ▼|AVGO367.78-2.56 (-0.69%) ▼|AXP326.86-3.32 (-1.00%) ▼|BA206.77-1.01 (-0.49%) ▼|BAC62.37+0.43 (+0.69%) ▲|BKNG199.46+0.37 (+0.18%) ▲|BLK1,136.45-19.16 (-1.66%) ▼|BMY67.03+0.22 (+0.32%) ▲|BNY160.60-0.68 (-0.42%) ▼|BRK-B504.70+0.67 (+0.13%) ▲|C133.09+1.47 (+1.11%) ▲|CAT781.69-15.78 (-1.98%) ▼|CL90.56+0.74 (+0.83%) ▲|CMCSA26.55-0.07 (-0.26%) ▼|COF213.56-0.96 (-0.45%) ▼|COP135.00+2.51 (+1.89%) ▲|COST945.38+1.49 (+0.16%) ▲|CRM257.80+0.26 (+0.10%) ▲|CSCO109.17-1.33 (-1.20%) ▼|CVS97.09+3.18 (+3.39%) ▲|CVX208.95+2.81 (+1.36%) ▲|DE672.81+17.90 (+2.73%) ▲|DHR209.33-4.24 (-1.98%) ▼|DIS107.52-0.03 (-0.03%) ▼|DUK120.65+0.74 (+0.61%) ▲|EMR149.65-2.79 (-1.83%) ▼|FDX324.60-2.80 (-0.86%) ▼|GD369.27-2.09 (-0.56%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV884.54-13.99 (-1.56%) ▼|GILD148.38+2.04 (+1.39%) ▲|GM86.22-0.10 (-0.12%) ▼|GOOG332.96-2.45 (-0.73%) ▼|GOOGL336.07-3.29 (-0.97%) ▼|GS1,021.55+0.65 (+0.06%) ▲|HD321.78-6.06 (-1.85%) ▼|HON210.33-3.20 (-1.50%) ▼|IBM231.12-2.75 (-1.18%) ▼|INTC88.80-0.71 (-0.79%) ▼|INTU349.87-9.43 (-2.62%) ▼|ISRG368.92-7.94 (-2.11%) ▼|JNJ268.15+2.30 (+0.86%) ▲|JPM358.40+2.38 (+0.67%) ▲|KO88.53-0.14 (-0.16%) ▼|LIN483.89-5.69 (-1.16%) ▼|LLY1,171.93+15.20 (+1.31%) ▲|LMT551.37-6.41 (-1.15%) ▼|LOW201.78-2.92 (-1.43%) ▼|LRCX291.64-9.85 (-3.27%) ▼|MA587.12-2.19 (-0.37%) ▼|MCD261.14-0.54 (-0.21%) ▼|MDLZ62.38+0.31 (+0.50%) ▲|MDT91.80+1.15 (+1.27%) ▲|META578.60+6.26 (+1.09%) ▲|MMM170.74-1.09 (-0.63%) ▼|MO70.38+1.90 (+2.77%) ▲|MRK149.39+1.63 (+1.10%) ▲|MS214.04+0.72 (+0.34%) ▲|MSFT501.12-6.18 (-1.22%) ▼|MU954.46-4.28 (-0.45%) ▼|NEE82.79+0.45 (+0.55%) ▲|NFLX80.88-0.18 (-0.22%) ▼|NKE38.36-0.30 (-0.76%) ▼|NOW143.09-4.91 (-3.31%) ▼|NVDA218.48-2.02 (-0.92%) ▼|ORCL142.52-6.60 (-4.43%) ▼|PEP140.01-0.33 (-0.24%) ▼|PFE28.64+0.18 (+0.61%) ▲|PG147.83+2.71 (+1.87%) ▲|PLTR183.27-3.11 (-1.67%) ▼|PM190.77+3.47 (+1.85%) ▲|QCOM165.61-4.87 (-2.86%) ▼|RTX206.16-1.58 (-0.76%) ▼|SBUX105.83-0.42 (-0.40%) ▼|SCHW108.78-1.04 (-0.95%) ▼|SO88.11+0.11 (+0.13%) ▲|SPG213.04+0.72 (+0.34%) ▲|T26.07+0.18 (+0.70%) ▲|TMO604.86-12.24 (-1.98%) ▼|TMUS181.95+1.51 (+0.84%) ▲|TSLA359.27-8.68 (-2.36%) ▼|TXN253.38-7.53 (-2.89%) ▼|UBER75.44-0.21 (-0.28%) ▼|UNH395.95+6.54 (+1.68%) ▲|UNP293.91-6.76 (-2.25%) ▼|UPS102.78-1.46 (-1.40%) ▼|USB61.23-0.36 (-0.58%) ▼|V376.86-2.52 (-0.66%) ▼|VZ50.30+0.28 (+0.55%) ▲|WFC86.87+0.48 (+0.55%) ▲|WMT106.07+1.20 (+1.14%) ▲|XOM163.12+2.17 (+1.35%) ▲|
24.1 C
New York
Tuesday, September 1, 2026

Tag: injection

newssourceFORcompanyinformationcontent1releasesmarket

Alteogen Showcases ALT-B4’s Potential to Transform ADC Development at World ADC Summit 2026

Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapyKey PointsSuperior PK: Subcutaneous administration of ADCs...

FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...

Peptide Tracker Launches Full Visual Redesign and New Safety Features for Peptide Protocol Tracking

A Rebuilt iOS Experience Adds Multi-Compound Blends, Per-Compound Concentrations, and a Visual Dose Guide That Shows Exactly How Much to Draw and What You...

Agent Governance Platform from Ares® Networks Now Available in the Microsoft Marketplace

Microsoft Azure customers worldwide can now discover and deploy the Ares® Networks Agent Governance Platform through Microsoft Marketplace, accessing trusted solutions that accelerate innovation...

Clear Robotics Lands $1.75M to Build the World’s Largest Fleet of Zero-Emission Autonomous Ships

HONG KONG, June 8, 2026 /PRNewswire/ -- Today, Clear Robotics, a Hong Kong founded maritime technology company, announced that it closed a $1.75 million...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInjection

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers